
|Articles|May 7, 2007
New drop to clear conjunctivitis
AzaSite (azithromycin ophthalmic solution) 1% has been approved by the FDA.
Advertisement
New drop to clear conjunctivitis By the third quarter of 2007, a new treatment for bacterial conjunctivitis will be available from Inspire Pharmaceuticals. AzaSite (azithromycin ophthalmic solution) 1% has been approved by the FDA and, according to the manufacturer, will offer patients a reduced dosing regimen compared with other available products for treating the condition. One drop twice-daily for two days, followed by one drop once-daily for the next five days, for a total of nine drops in the affected eye, is the recommended dosing schedule.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
What’s Next for Pneumococcal Vaccination? An Expert Weighs In
5






























